Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer

NCT01348126 is registered in ClinicalTrials.gov with Synta Pharmaceuticals Corp. as lead sponsor.

NCT NCT01348126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01348126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer
Lead sponsor
Synta Pharmaceuticals Corp.
Phase
Phase 2/3
Overall status
Terminated
Start date
May 31, 2011
Completion date
October 31, 2015
Enrollment
385 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic, non-small cell lung cancer stage iiib, non-small cell lung cancer stage iv